Biohacking Kompakt

Supplement

Glucosamine

Longevity · glucosamine sulfate

Glucosamine is a building block of cartilage and a widely used remedy for joint complaints – according to the US database LiverTox, millions of people take it. It has been studied exceptionally thoroughly, with large trials and several meta-analyses. That is precisely why, with glucosamine, it is known fairly exactly what it can and cannot do.

In short

Glucosamine is exceptionally well tolerated; in the studies, side effects were at placebo level. For osteoarthritis pain, the result depends on the preparation: studies with a particular glucosamine sulfate sold as a medicine were positive, while large independent studies found no clinically relevant difference from placebo. The latest overview of 19 reviews sees a small effect on pain and a somewhat slower narrowing of the joint space, both at or below the threshold at which patients notice a difference. The link to longer life expectancy comes from observational data that can be heavily biased. Anyone taking coumarin blood thinners or who has diabetes should clarify the intake beforehand.

What it is

Glucosamine is an amino sugar and a building block of cartilage. For preparations, it is usually obtained from the shells of crustaceans or produced by fermentation of cereals.

On the market there are two worlds. In Germany, glucosamine hemisulfate is available as a pharmacy-only medicine for relieving the symptoms of mild to moderate knee osteoarthritis; one such sachet contains 1,500 mg of glucosamine hemisulfate. In addition there are numerous food supplements with glucosamine sulfate or glucosamine hydrochloride, often combined with chondroitin.

How it is supposed to work

The idea is simple: if cartilage needs glucosamine as a building block, additional glucosamine should support its build-up and slow its breakdown.

In humans, this chain has not been measured through. In 2012 the European Food Safety Authority examined whether glucosamine maintains normal joint cartilage and found no human studies in people without osteoarthritis from which this could be derived. The authority rated the submitted cell and animal data on biological plausibility as weak.

Why so many feel an improvement

Glucosamine has been taken for decades, and many users report that their knee has got better. These reports are real, and there is a study that tested them directly. A research group recruited 137 users with knee osteoarthritis who had experienced at least moderate improvement since starting to take it. Half continued taking glucosamine, the other half unknowingly received placebo. After 6 months, 42 % had a flare under placebo, 45 % under glucosamine.

A second finding helps with the assessment: in the large US study GAIT, 60.1 % of participants under placebo achieved a pain improvement of at least 20 %. Osteoarthritis pain therefore changes markedly even without an active ingredient. That does not make the reports wrong, but it explains why a statement about the substance requires a comparison with placebo.

What is well supported

Safety is very well supported. In the Cochrane review, side effects were at placebo level, and the latest overview from 2026 also finds no higher rates than under placebo. The good tolerability is thus broadly established.

On benefit, there is a small but measurable finding. The 2026 umbrella review pools 19 reviews and finds a statistically significant pain reduction on the visual pain scale and a somewhat slower narrowing of the joint space, the latter mainly from long studies with glucosamine sulfate. Most clearly positive were the studies with the preparation from the manufacturer Rotta, a patent-protected glucosamine sulfate sold as a medicine: in 10 placebo-controlled studies it was clearly superior for pain, and 2 studies over 3 years showed slower radiological worsening of the knee. A review by the author group of these studies also reports 50 % fewer osteoarthritis-related operations on the legs in the 5 years after the end of treatment. That is a remarkable finding, but it comes from the author group itself and not from a separate randomized trial.

What the studies show

Cochrane review 2005: the result depends on the preparation

The review covers 25 studies with 4,963 patients; 20 studies with 2,570 patients were pooled. Across all studies there was 28 % less pain and 21 % better function in the Lequesne index, but no significant difference in the WOMAC scores. In the 8 methodologically cleanest studies with concealed allocation, the advantage disappeared. The Rotta preparation was superior, other preparations were not.

GAIT 2006: 1,583 patients, primary goal missed

The US study compared 1,500 mg of glucosamine daily, chondroitin, the combination, the painkiller celecoxib and placebo over 24 weeks. Glucosamine was 3.9 percentage points above placebo, which was not significant, whereas celecoxib was. In the subgroup with moderate to severe pain, 79.2 % responded to the combination with chondroitin and 54.3 % to placebo. The authors regard this as an exploratory signal.

Network meta-analysis 2010: below the threshold of noticeability

Wandel and colleagues analyzed 10 large studies with 3,803 patients. Glucosamine reduced pain on a 10 cm scale by 0.4 cm compared with placebo. The authors had set 0.9 cm in advance as clinically relevant. Studies without industry funding showed smaller effects than funded ones.

Umbrella review 2026: small but measurable

Li and colleagues pooled 19 reviews up to November 2025. Pain on the analog scale fell slightly (SMD −0.36), WOMAC pain did not, function did not. Joint space narrowing proceeded more slowly (SMD −0.32). All effects were at or below the threshold of clinical relevance, and the quality of most reviews was low.

Where the data stop

Why the Rotta studies turned out positive and the independent ones negative cannot be reliably separated from the data. Differences in the preparation and the influence of funding are both possible, and both are discussed in the literature. What is clear: independent studies with glucosamine sulfate 1,500 mg once daily also found no difference, for example in 222 patients with hip osteoarthritis over 2 years. And a new 2026 study with 216 participants likewise found no superiority over placebo after 24 weeks with prescription crystalline glucosamine sulfate. Structural protection rests on 2 studies over 3 years; GAIT found no difference after 2 years.

The mortality data sound strong: in the UK Biobank with 495,077 people, the hazard ratio for all-cause mortality among glucosamine users was 0.85, that is, arithmetically below that of non-users. A methodological analysis shows, however, that exactly this study design can push a true ratio of 1.0 down to 0.82, because only people are captured who were already taking glucosamine and wanted to take part in the cohort. A study that avoids this does not yet exist. For healthy people without osteoarthritis, data on prevention are lacking entirely.

Status, approval and legal

In Germany, glucosamine hemisulfate is sold as a pharmacy-only medicine for relieving the symptoms of mild to moderate knee osteoarthritis. As a food supplement, according to the Verbraucherzentrale (German consumer advice centre), glucosamine may no longer be advertised with healthy joints, mobility or cartilage formation, because in 2012 EFSA did not consider the effect on cartilage maintenance in healthy people to be established. The guidelines are inconsistent: the US rheumatologists, the Arthritis Foundation and the international osteoarthritis society OARSI advise against it; the European society ESCEO and the US orthopedic surgeons see a limited possible benefit. For competitive athletes, the general NADA advice on contamination of food supplements applies.

Safety

Tolerability is well documented over decades and thousands of study participants; side effects did not occur more often than under placebo. The US liver database LiverTox lists glucosamine as a possible rare cause of liver injury. Three points are important: with the blood thinner warfarin and other coumarins, an increased risk of bleeding has been described. Glucosamine can raise blood sugar in some people; in diabetes, monitoring is recommended. And glucosamine from crustaceans can be problematic in people with a shellfish allergy; there are variants from cereal fermentation. For pregnant women, breastfeeding women, children and adolescents, no assessment is possible due to a lack of data.

BK-Score Well studied – effect not confirmed

Human evidence8
Mechanism4
Safety data9
Hype gap4
Track record of use9

Human evidence 8 rather than 7: large RCTs (GAIT with 1,583 patients over 24 weeks, follow-up studies over 2 years) and several meta-analyses with clinical endpoints. The Cochrane review (Towheed et al., CD002946) analyzes 25 studies with 4,963 osteoarthritis patients – and the result depends on the preparation and study quality: across 20 pooled studies with 2,570 patients, glucosamine was superior to placebo, with 28 percent less pain and 21 percent better function in the Lequesne index; the WOMAC scores for pain, function and stiffness did not become significant. If the analysis is restricted to the 8 studies with concealed allocation, the advantage for pain and WOMAC function disappears. Only the Rotta preparation was consistently superior; whether this is due to the formulation or to the funding cannot be separated from the data – industry-independent studies showed smaller effects (Wandel, BMJ 2010), and independent studies with glucosamine sulfate 1,500 mg once daily also remained without effect. The overview of 19 reviews (2026) finds small effects at or below the relevance threshold. The direction remains negative: the independent data speak against the advertised, noticeable pain benefit. Safety has been studied excellently over decades and thousands of participants and is at placebo level.

The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)

Frequently asked questions about glucosamine

How much glucosamine was taken in the studies?

The large studies used 1,500 mg daily, either once a day as sulfate or split into 3 doses of 500 mg. The German medicine contains 1,500 mg of glucosamine hemisulfate per sachet. This is a description of the studies, not a personal recommendation.

Is glucosamine sulfate better than glucosamine hydrochloride?

The positive studies were mostly done with the glucosamine sulfate of one particular manufacturer. Whether the salt form makes the difference has not been clarified, because independent studies with glucosamine sulfate also found no effect. A direct, independent comparison of the forms is lacking.

Does glucosamine rebuild cartilage?

There is no evidence for that. Two studies over 3 years showed a somewhat slower narrowing of the joint space, other long-term studies did not. No study has shown a rebuilding of cartilage, and exactly this advertising claim is not permitted.

How long does it take for glucosamine to work?

The studies mostly ran for 24 weeks to 3 years. The Cochrane estimates refer to about 6 months. Anyone who feels no difference after a few months is within the range of what the independent studies found.

Can I take glucosamine with blood thinners?

With warfarin and other coumarins, an increased risk of bleeding has been described. The Verbraucherzentrale explicitly names this as a risk. In this case, the intake should be discussed with a doctor.

Does glucosamine extend life?

Large observational studies found lower mortality among users. A methodological analysis shows that this finding can arise from the way the data were collected. A causal relationship is not established.

Related

Sources

Open in the database – with search, filters and comparison (German app)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-26.